EUVIMEDEUVIMED entdecken
Open Access

Rationale and design of the Adipose Dysfunction, Imaging, Physiology, and Outcomes with sodium-glucose cotransporter − 2 inhibitors for Sleep Apnea (ADIPOSA) study

Ehimen Aneni, Isaac Karim, Joe Rutter, Opemipo Olaseni, Iouri Kreinin, Sui Tsang, Zuoheng Wang, Kingman P Strohl, H Klar Yaggi, Ian J Neeland

Contemporary Clinical Trials · 2025

DOI: 10.1016/j.cct.2025.108134 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2025. Verfasst von Ehimen Aneni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States of America. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Sleep Apnea, Obstructive, Obesity. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Obstructive sleep apnea (OSA) is a chronic condition that is associated with significant morbidity and mortality. Positive airway pressure (PAP) therapy is the gold-standard treatment for OSA but has low adherence rates. Observational studies, including post-hoc analyses of clinical trials, suggest an association between treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) and reduction in incident or diminished severity of prevalent OSA. However, the effects of SGLT2i therapy on the clinical severity of OSA and its mechanistic relation to underlying OSA pathophysiology have not been tested in a randomized clinical trial. METHODS AND RESULTS: The Adipose Dysfunction, Imaging, Physiology, and Outcomes with SGLT2i's for Sleep Apnea (ADIPOSA) study is a double-blind, randomized, placebo-controlled clinical trial that will enroll 164 patients with overweight/obesity and moderate to severe OSA across two sites (Cleveland, OH and New Haven, CT). All participants will complete medical history and sleep questionnaires and undergo ambulatory polysomnography, neck and body fat imaging, 7-day actigraphy, 24-h ambulatory blood pressure monitoring, and a blood draw at baseline and 6-month follow-up. Patients will be randomized 1:1 to receive either bexagliflozin 20 mg once daily or a matching placebo. The primary outcome is a reduction in the apnea-hypopnea index, and secondary outcomes include changes in sleep health, body fat distribution, blood pressure, activity, and biomarkers of inflammation and metabolism. CONCLUSIONS: The ADIPOSA study will identify the mechanisms underlying the effects of SGLT2i on OSA while providing evidence for future investigation to test the efficacy of pharmacologic SGLT2i on OSA prevention and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsSleep Apnea, ObstructiveObesityHumansDouble-Blind MethodPolysomnographyRandomized Controlled Trials as TopicMaleFemaleAdultMiddle AgedAdipose TissueSeverity of Illness IndexOverweightContinuous Positive Airway PressureMulticenter Studies as Topic

Stichwörter der Autor:innen

Body fat distributionDiabetesObesityObstructive sleep apneaSleep disordersSodium glucose co-transporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States of America.
  • Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, United States of America.
  • Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, United States of America.
  • Department of Biostatistics, Yale School of Public Health, New Haven, CT, United States of America.
  • Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Case Western Reserve University, Cleveland, OH, United States of America.
  • Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, United States of America. Electronic address: henry.yaggi@yale.edu.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Aneni, E., Karim, I., Rutter, J., Olaseni, O., Kreinin, I., Tsang, S., Wang, Z., Strohl, K. P., Yaggi, H. K., & Neeland, I. J. (2025). Rationale and design of the Adipose Dysfunction, Imaging, Physiology, and Outcomes with sodium-glucose cotransporter − 2 inhibitors for Sleep Apnea (ADIPOSA) study. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2025.108134

Vancouver

Aneni E, Karim I, Rutter J, Olaseni O, Kreinin I, Tsang S, et al. Rationale and design of the Adipose Dysfunction, Imaging, Physiology, and Outcomes with sodium-glucose cotransporter − 2 inhibitors for Sleep Apnea (ADIPOSA) study. Contemporary Clinical Trials. 2025. doi:10.1016/j.cct.2025.108134

BibTeX
@article{Aneni2025,
  author = {Aneni, Ehimen and Karim, Isaac and Rutter, Joe and Olaseni, Opemipo and Kreinin, Iouri and Tsang, Sui and Wang, Zuoheng and Strohl, Kingman P and Yaggi, H Klar and Neeland, Ian J},
  title = {Rationale and design of the Adipose Dysfunction, Imaging, Physiology, and Outcomes with sodium-glucose cotransporter − 2 inhibitors for Sleep Apnea (ADIPOSA) study},
  journal = {Contemporary Clinical Trials},
  year = {2025},
  doi = {10.1016/j.cct.2025.108134}
}
Kostenlos starten →